Breaking Down Biologics in Atopic Dermatitis: Choosing the Right Path for Patients - Episode 8
Safety of Biologics in Atopic Dermatitis Treatment
Panelists discuss how biologics for atopic dermatitis demonstrate excellent safety profiles with primarily mild, manageable adverse effects such as injection site reactions, conjunctivitis (particularly with dupilumab), mild infections, and headaches. However, they note that successful management requires transparent discussions with patients about realistic treatment expectations (typically emphasizing gradual improvement rather than immediate resolution), systematic monitoring protocols combining objective assessments (EASI/BSA/IGA) with patient-reported outcomes (itch severity, sleep quality, quality-of-life measures), appropriate timing of evaluation intervals, laboratory monitoring when indicated, and clear communication about what constitutes a meaningful response vs the need to consider therapeutic adjustments.
Video content above is prompted by the following:
- What are some of the most common adverse effects that you see with biologics in clinical practice?
- How do you discuss the efficacy and safety of biologics for atopic dermatitis with your patients and their families?
- How do you set treatment expectations with your patients, and how do you monitor for safety and effectiveness of treatment with biologics?
